Shree Cement Ltd
SHREECEMShree Cement Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +55.3% against a −15.1% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (37 weeks in) while the P/E sits at the 80th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −17.5% year on year, and 229% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Shree Cement Ltd trades at ₹26,055, in a downtrend and 37 weeks into that stage. That is −0.5% against its own 200-day average. It sits at 45% of a 52-week range of ₹22,965 to ₹29,880. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a downtrend — week 37 of stage 4. At ₹26,055 it trades −0.5% versus its 200-day average and sits at 45% of its 52-week range (₹22,965–₹29,880).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +131% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Shree Cement Ltd trades at 57.7× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 50.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 57.7× is at the pricey end of its own range (80th percentile), against a long-run median of 50.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +55.3% against a −15.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −1.6%/yr price move, ~−6.4%/yr came from earnings growth and ~+4.8 pp from the multiple (expanding); over 10y, of the +4.9%/yr price move, ~+3.3%/yr came from earnings growth and ~+1.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Shree Cement Ltd reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 10.0% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.6% | +5.5% | +9.1% | +14.3% |
| Profit | +55.6% | +11.3% | −5.2% | +4.3% |
| EPS | +55.3% | +11.1% | −5.3% | +3.9% |
| Share price | −15.1% | +2.7% | −1.6% | +4.9% |
4-Factor Sector Score
51.8/100 — rank 8 of 26 in Cement · 97% evidence confidence
Shree Cement Ltd scores 51.8 out of 100 against the 26 companies it is compared with in Cement, ranking 8. Price leads the evidence: RS versus the benchmark is -3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 15 + 13 + 9.2 + 14.6 = 51.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Shree Cement Ltd reported ₹6,233 Cr of revenue in the Jun 26 quarter, +18.0% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 14.3% a year. The last full year, FY26, came in at ₹20,943 Cr. The last four reported quarters add to ₹21,896 Cr.
FY26 revenue came in at ₹20,943 Cr (+8.6% on the year), capping 10 years at 14.3% compound. The latest quarter (Jun 26) printed ₹6,233 Cr, +18.0% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.7% growth against the decade's 14.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +12.6% over the last 4 quarters against +3.4%/yr over the last 8 — accelerating; TTM profit +9.9% vs −11.8%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Shree Cement Ltd's operating margin is 20.0% in the Jun 26 quarter, −5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0% to 30.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, −5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0%–30.0%.
🚨 Why the margin moved: operating margin went −4.8 pp year on year while gross margin went −3.4 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Shree Cement Ltd earned ₹531 Cr of net profit in the Jun 26 quarter, −17.5% year on year. Full-year FY26 profit was ₹1,749 Cr. The 10-year compound rate is 4.3%. That is 8.5% of the quarter's revenue. The same quarter a year earlier earned ₹644 Cr.
Jun 26 profit was ₹531 Cr, −17.5% year on year. On the full year, FY26 printed ₹1,749 Cr (+55.6%), and the 10-year compound rate is 4.3%.
🚨 Why profit moved: revenue contributed +18.0% and the margin −5.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +78.8% vs revenue +12.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 229% of Shree Cement Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹3,794 Cr of operating cash against ₹1,749 Cr of profit. After ₹2,356 Cr of capital spending, ₹1,438 Cr was left as free cash.
FY26: operating cash of ₹3,794 Cr against reported profit of ₹1,749 Cr, leaving free cash of ₹1,438 Cr after ₹2,356 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 229% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 229%: the cash cycle tightened 75 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Shree Cement Ltd's cash conversion cycle runs 227 days in FY26, down from 302 days in FY21. Capital spending ran ₹10,093 Cr over the last 3 years. At FY26 sales of ₹20,943 Cr each day of that cycle holds about ₹57.4 Cr, so roughly ₹13,025 Cr sits inside the business at any moment.
FY26: debtors at 32 days, inventory at 469 days — roughly 15.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 227 days, tighter than FY21's 302.
The full loop: cash goes out to suppliers and production on day 0; stock waits 469 days to sell; customers pay about 32 days after that; and suppliers themselves are paid at 274 days — netting out to the 227-day cycle.
In money terms: at FY26 sales of ₹20,943 Cr, each day of the cycle holds about ₹57.4 Cr — so the 227-day loop keeps roughly ₹13,025 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹10,093 Cr over the last 3 fiscal years against ₹7,698 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹1,466 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Shree Cement Ltd earns a ROCE of 10% in FY26. That is up from a trough of 7% in FY25. Return on invested capital clears the cost of that capital by −3.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.4% net margin on 0.67× asset turns.
FY26 ROCE is 10%, recovered from a FY25 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 8.4% net margin × 0.67× asset turns × 1.35× balance-sheet leverage ≈ 7.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 8.1% − 12.0% = a −3.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Shree Cement Ltd carries total debt of ₹1,868 Cr against shareholder equity of ₹23,314 Cr as of Jun 26, a debt-to-equity of 0.08 — effectively unlevered. On the annual view that ratio went from 0.12 in FY22 to 0.08 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹1,868 Cr against shareholder equity of ₹23,314 Cr — a debt-to-equity of 0.08. On the annual view, debt-to-equity went from 0.12 (FY22) to 0.08 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 3.6 points of Shree Cement Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 8.2% of the company. Domestic institutions moved +3.6 points over the same window, to 16.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −3.6 points over 8 quarters to 8.2%; Domestic institutions: +3.6 points over 8 quarters to 16.4%; Promoters: +0.0 points over 8 quarters to 62.6%.
Why the register moved: rotation — foreign institutions −3.6 points against domestic institutions +3.6 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Shree Cement Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Star Cement LtdSTARCEMENT | 76.0/100Favorable setup90% evidence | ASLEEP | 29.9/35 Revenue 19.4% · PAT 100% · OPM change 2 pp 88% evidence | 22.4/25 ROCE 16.7% · OPM 27% 100% evidence | 11.3/20 P/E 20.4× · PEG 1.11 100% evidence | 12.4/20 RS sector 13.8% · RS bench -13.2% · 1Y -12.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 29.9 + 22.4 + 11.3 + 12.4 = 76 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NCL Industries LtdNCLIND | 69.7/100Favorable setup83% evidence | FADING | 25.3/35 Revenue 1.8% · PAT 100% · OPM change 7 pp 83% evidence | 18.0/25 ROCE 14.5% · OPM 13% 95% evidence | 15.0/20 P/E 6.3× · PEG — 50% evidence | 11.4/20 RS sector 2.1% · RS bench -6.3% · 1Y -18.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 18 + 15 + 11.4 = 69.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3UltraTech Cement LtdULTRACEMCO | 63.1/100Mixed-positive evidence76% evidence | TURNING | 21.9/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.2/20 P/E 40.7× · PEG — 50% evidence | 14.9/20 RS sector 17% · RS bench -1.4% · 1Y -2.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 17.1 + 9.2 + 14.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Mangalam Cement LtdMANGLMCEM | 62.9/100Mixed-positive evidence96% evidence | FADING | 21.6/35 Revenue 4.6% · PAT 100% · OPM change 0 pp 88% evidence | 11.7/25 ROCE 11% · OPM 11% 100% evidence | 16.0/20 P/E 17.5× · PEG 0.6 100% evidence | 13.6/20 RS sector 24.1% · RS bench 14.9% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.7 + 16 + 13.6 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rain Industries LtdRAIN | 62.5/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.9/35 Revenue 14.4% · PAT 100% · OPM change 5 pp 62% evidence | 9.4/25 ROCE 8.3% · OPM 15% 76% evidence | 10.2/20 P/E 24.9× · PEG — 15% evidence | 20.0/20 RS sector 61.8% · RS bench 49.7% · 1Y 43.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 9.4 + 10.2 + 20 = 62.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Orient Cement LtdORIENTCEM | 58.2/100Mixed-positive evidence93% evidence | ASLEEP | 17.6/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 13.2× · PEG 0.25 65% evidence | 7.6/20 RS sector -12% · RS bench -20.1% · 1Y -45.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.9 + 16.1 + 7.6 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Dalmia Bharat LtdDALBHARAT | 53.4/100Mixed-positive evidence94% evidence | ASLEEP | 13.0/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 12.8/25 ROCE 7.6% · OPM 21% 100% evidence | 15.3/20 P/E 30.7× · PEG 0.72 100% evidence | 12.3/20 RS sector 12.6% · RS bench -11.9% · 1Y -19.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 12.8 + 15.3 + 12.3 = 53.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Shree Cement Ltdthis pageSHREECEM | 51.8/100Mixed-positive evidence97% evidence | BREAKING OUT | 15.0/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 95% evidence | 13.0/25 ROCE 10.3% · OPM 20% 95% evidence | 9.2/20 P/E 57.7× · PEG 0.96 100% evidence | 14.6/20 RS sector 5.1% · RS bench -3.7% · 1Y -15.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 13 + 9.2 + 14.6 = 51.8 · Decision use: Price leads the evidence: RS versus the benchmark is -3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9JSW Cement LtdJSWCEMENT | 50.8/100Thin evidence · provisional51% evidence | TURNING | 18.6/35 Revenue 12% · PAT -80% · OPM change 5 pp 83% evidence | 12.1/25 ROCE 11.1% · OPM 19% 76% evidence | 10.1/20 P/E 27.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -8.9%5 of 10 weeks ahead 0% evidence |
| Exact sum: 18.6 + 12.1 + 10.1 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10K C P LtdKCP | 49.4/100Mixed-negative evidence77% evidence | ASLEEP | 13.5/35 Revenue 1.9% · PAT 8.7% · OPM change 1 pp 83% evidence | 16.1/25 ROCE 12.2% · OPM 17% 95% evidence | 13.9/20 P/E 10.3× · PEG — 50% evidence | 5.9/20 RS sector -14% · RS bench -9.4% · 1Y -23.5%3 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 16.1 + 13.9 + 5.9 = 49.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11HeidelbergCement India LtdHEIDELBERG | 48.6/100Mixed-negative evidence100% evidence | ASLEEP | 14.5/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.7/25 ROCE 14.7% · OPM 11% 100% evidence | 13.7/20 P/E 28.5× · PEG 0.82 100% evidence | 5.7/20 RS sector -5.1% · RS bench -13.3% · 1Y -28.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.7 + 13.7 + 5.7 = 48.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12J K Cements LtdJKCEMENT | 48.1/100Mixed-negative evidence94% evidence | TURNING | 11.2/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.4/25 ROCE 15.1% · OPM 16% 100% evidence | 8.1/20 P/E 43.1× · PEG 1.46 100% evidence | 12.4/20 RS sector 10.4% · RS bench -7.1% · 1Y -16%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 16.4 + 8.1 + 12.4 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13The Ramco Cements LtdRAMCOCEM | 47.3/100Mixed-negative evidence90% evidence | ASLEEP | 20.6/35 Revenue 6% · PAT 100% · OPM change 1 pp 88% evidence | 13.2/25 ROCE 6.1% · OPM 14% 100% evidence | 1.2/20 P/E 732× · PEG 4.14 100% evidence | 12.3/20 RS sector 11.1% · RS bench -10.1% · 1Y -19.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 13.2 + 1.2 + 12.3 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14JK Lakshmi Cement LtdJKLAKSHMI | 47.3/100Mixed-negative evidence65% evidence | ASLEEP | 17.4/35 Revenue 9.2% · PAT 49.6% · OPM change -5 pp 83% evidence | 13.9/25 ROCE 12% · OPM 14% 76% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 5.4/20 RS sector -8.2% · RS bench -23.6% · 1Y -40.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.4 + 13.9 + 10.6 + 5.4 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Nuvoco Vistas Corporation LtdNUVOCO | 47.1/100Mixed-negative evidence87% evidence | TURNING | 21.0/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 9.6/25 ROCE 7.1% · OPM 18% 100% evidence | 4.8/20 P/E 29.7× · PEG 8.14 65% evidence | 11.7/20 RS sector 3.6% · RS bench -5% · 1Y -16.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 9.6 + 4.8 + 11.7 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16India Cements LtdINDIACEM | 45.4/100Mixed-negative evidence75% evidence | ASLEEP | 21.3/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.8/25 ROCE 1.2% · OPM 15% 100% evidence | 5.4/20 P/E 91.4× · PEG — 50% evidence | 14.9/20 RS sector 20% · RS bench -2% · 1Y 10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.3 + 3.8 + 5.4 + 14.9 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Deccan Cements LtdDECCANCE | 43.7/100Mixed-negative evidence70% evidence | ASLEEP | 22.6/35 Revenue 20.6% · PAT 100% · OPM change -3 pp 83% evidence | 7.9/25 ROCE 3.3% · OPM 8.1% 95% evidence | 9.1/20 P/E 43.4× · PEG — 15% evidence | 4.1/20 RS sector -12.9% · RS bench -29.1% · 1Y -47.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.6 + 7.9 + 9.1 + 4.1 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18ACC LtdACC | 42.5/100Mixed-negative evidence94% evidence | ASLEEP | 9.1/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.9/25 ROCE 11.2% · OPM 8% 100% evidence | 16.7/20 P/E 13.4× · PEG 0.92 100% evidence | 6.8/20 RS sector -6.7% · RS bench -16.8% · 1Y -26.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 9.9 + 16.7 + 6.8 = 42.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Birla Corporation LtdBIRLACORPN | 41.0/100Mixed-negative evidence94% evidence | ASLEEP | 17.4/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 10.4/25 ROCE 9.8% · OPM 13% 100% evidence | 8.8/20 P/E 12.3× · PEG 3.92 100% evidence | 4.4/20 RS sector -14% · RS bench -17.4% · 1Y -37.4%3 of 9 weeks ahead 70% evidence |
| Exact sum: 17.4 + 10.4 + 8.8 + 4.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Sagar Cements LtdSAGCEM | 41.0/100Mixed-negative evidence66% evidence | ASLEEP | 19.5/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.1/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -8.1% · RS bench -16.3% · 1Y -28.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 5.1 + 10 + 6.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 38.9/100Mixed-negative evidence82% evidence | ASLEEP | 9.4/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.6/20 P/E 22.8× · PEG — 50% evidence | 5.9/20 RS sector -7.2% · RS bench -15.1% · 1Y -29.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 11 + 12.6 + 5.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Saurashtra Cement LtdSAURASHCEM | 38.8/100Mixed-negative evidence76% evidence | ASLEEP | 19.7/35 Revenue 8.4% · PAT 87.5% · OPM change -5 pp 83% evidence | 4.8/25 ROCE 2.5% · OPM 6% 95% evidence | 9.5/20 P/E 30.9× · PEG — 15% evidence | 4.8/20 RS sector -16.6% · RS bench -24.6% · 1Y -41.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 4.8 + 9.5 + 4.8 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Prism Johnson LtdPRSMJOHNSN | 38.2/100Mixed-negative evidence69% evidence | ASLEEP | 12.1/35 Revenue 6.3% · PAT -33.3% · OPM change -2 pp 83% evidence | 5.9/25 ROCE 5.9% · OPM 8% 76% evidence | 8.6/20 P/E — · PEG — 35% evidence | 11.6/20 RS sector 14.3% · RS bench -20.9% · 1Y -32.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 5.9 + 8.6 + 11.6 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BIGBLOC Construction LtdBIGBLOC | 36.7/100Thin evidence · provisional59% evidence | ASLEEP | 15.4/35 Revenue 26.2% · PAT -80% · OPM change -1.6 pp 62% evidence | 5.8/25 ROCE 1.8% · OPM 7.3% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -9.7% · RS bench -17.9% · 1Y -24.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 5.8 + 10 + 5.5 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Shree Digvijay Cement Co. LtdSHREDIGCEM | 31.2/100Adverse evidence81% evidence | ASLEEP | 10.8/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.2/25 ROCE 6.4% · OPM 8.7% 95% evidence | 6.1/20 P/E 59.4× · PEG — 50% evidence | 6.1/20 RS sector -12.4% · RS bench -10.9% · 1Y -15.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 10.8 + 8.2 + 6.1 + 6.1 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shiva Cement LtdSHIVACEM | 36.5/100Thin evidence · provisional42% evidence | 18.1/35 Revenue 19.7% · PAT -47.1% · OPM change 15 pp 40% evidence | 5.4/25 ROCE -3% · OPM 1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -27.5% · RS bench -36.4% · 1Y -54.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 18.1 + 5.4 + 10 + 3 = 36.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Shree Cement Ltd's share price today?
Shree Cement Ltd trades at ₹26,055, −15.1% over the past year. The company is valued at ₹94,008 Cr. The stock sits at 45% of its 52-week range of ₹22,965–₹29,880, −0.5% versus its 200-day average. On the tape, the price is in a downtrend, 37 weeks in. — as of 31 July 2026.
What were Shree Cement Ltd's latest quarterly results?
Shree Cement Ltd reported revenue of ₹6,233 Cr and net profit of ₹531 Cr for the Jun 26 quarter. Revenue rose 18.0% and profit fell 17.5% year on year. Earnings per share were ₹146.67. The operating margin was 20.0%, 5.0 pp lower than a year earlier. — as of 31 July 2026.
What is Shree Cement Ltd's revenue?
Shree Cement Ltd reported revenue of ₹6,233 Cr in the Jun 26 quarter, +18.0% year on year. For the full FY26 fiscal year, revenue was ₹20,943 Cr (+8.6%). Over the last 10 years revenue compounded at 14.3% a year. — as of 31 July 2026.
What is Shree Cement Ltd's profit?
Shree Cement Ltd earned ₹531 Cr of net profit in the Jun 26 quarter, −17.5% year on year. Full-year FY26 profit was ₹1,749 Cr. The operating margin ran 20.0% in the latest quarter. — as of 31 July 2026.
What is Shree Cement Ltd's market cap?
Shree Cement Ltd's market capitalisation is ₹94,008 Cr at a share price of ₹26,055. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Shree Cement Ltd's P/E ratio?
Shree Cement Ltd trades at a P/E of 57.7×, at the 80th percentile of its own 10-year range, against a long-run median of 50.1×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Shree Cement Ltd pay a dividend?
Yes — Shree Cement Ltd's dividend payout was 31% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Shree Cement Ltd overvalued?
On its own history, Shree Cement Ltd looks expensive against its own history: its P/E of 57.7× sits at the 80th percentile of its 10-year range (long-run median 50.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Shree Cement Ltd growing?
Not right now — Shree Cement Ltd's latest numbers are shrinking: latest-quarter revenue +18.0% year on year, profit −17.5%, and the margin −5.0 pp at 20.0%. The 10-year compound rates are 14.3% (revenue) and 4.3% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Shree Cement Ltd performing?
Shree Cement Ltd is in a downtrend, 37 weeks in. Its latest quarter's revenue rose 18.0% and profit fell 17.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Shree Cement Ltd in?
Mixed — the growth curves are steadily positive, but ROCE at 10.0% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +12.6% latest, profit growth +9.9% latest, eps growth +9.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Shree Cement Ltd in an uptrend?
No — the price is in a downtrend (week 37 of stage 4), trading −0.5% versus its 200-day average and at 45% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Shree Cement Ltd beating the market?
On recent form, yes — Shree Cement Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +131% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Shree Cement Ltd's share price go up?
This page publishes no price forecast for Shree Cement Ltd. What it measures instead: the share price is ₹26,055, the price is in a downtrend 37 weeks in. Its P/E of 57.7× sits at the 80th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Shree Cement Ltd?
Promoters hold 62.6% of Shree Cement Ltd, foreign institutions 8.2%, domestic institutions 16.4% and the public 12.6% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 3.6 points over 8 quarters. — as of 31 July 2026.
Does Shree Cement Ltd have too much debt?
No — Shree Cement Ltd's debt-to-equity is 0.08, and operating profit covers the interest bill 22×. FY26 borrowings were ₹1,868 Cr against equity of ₹23,267 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Shree Cement Ltd's capex?
Shree Cement Ltd spent ₹10,093 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹2,356 Cr, with ₹1,466 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Shree Cement Ltd's cash flow?
Shree Cement Ltd generated ₹3,794 Cr of operating cash flow in FY26 and ₹1,438 Cr of free cash flow after ₹2,356 Cr of capital spending. Reported profit that year was ₹1,749 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Shree Cement Ltd's profit real cash?
Yes — over the last 3 fiscal years, 229% of Shree Cement Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹3,794 Cr against reported profit of ₹1,749 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Shree Cement Ltd in its business cycle?
Shree Cement Ltd's FY26 operating margin was 22.0%, against a 13-year band of 17.0%–30.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Shree Cement Ltd story?
The sharpest disagreement: annual EPS moved +55.3% against a −15.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Shree Cement Ltd a stock worth studying right now?
This is not investment advice. The machine read: Shree Cement Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.